Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 3/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6514910 | 0.81 | CHEK1 (0.49) | TSHRALDH1A1POLBLMNA | |
| SCHEMBL6518602 | 0.81 | AURKA (0.41) | GAATSHRALDH1A1MEN1KMT2A | |
| SCHEMBL21067780 | 0.80 | CYP1A2 (0.48) | GAAALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6523698 | 0.79 | TSHR (0.47) | TSHRALDH1A1POLBLMNA | |
| SCHEMBL6508661 | 0.79 | TOP2A (0.53) | SMN1; SMN2 | |
| SCHEMBL6515436 | 0.79 | CHEK1 (0.51) | GAAALDH1A1POLBLMNA | |
| Hydrochloric Acid SCHEMBL6518743 | 0.78 | TOP2A (0.52) | SMN1; SMN2 | |
| SCHEMBL6519265 | 0.77 | HTR7 (0.47) | TSHRALDH1A1 | |
| SCHEMBL6514357 | 0.76 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2APOLBLMNA | |
| SCHEMBL6521770 | 0.75 | HDAC3 (0.40) | ALDH1A1SMN1; SMN2MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | GAA 2750/4885TSHR 4004/4885ALDH1A1 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.